AMENDMENTS TO THE CLAIMS

1-45. (Canceled).

46. (Currently Amended) A method for preventing and/or treating an amyloid-related disease in a subject, comprising administering to said subject a vaccine for generating anti-amyloidogenic antibodies, wherein said vaccine comprises a peptide comprising an amino acid sequence as set forth in SEQ ID NO: 13 and an adjuvant, and the amino acids of SEQ ID NO: 13 consist entirely of [D]-amino acids.

47. (Previously Presented) The method of claim 46, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 56, SEQ ID NO: 59, and SEQ ID NO: 62.

48. (Previously Presented) The method of claim 47, wherein said amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 56, SEQ ID NO: 59, or SEQ ID NO: 62 consists entirely of [D]-amino acids.

49. (Previously Presented) The method of claim 46, wherein said peptide is made entirely of [D]-amino acids and comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 56, SEQ ID NO: 59, and SEQ ID NO: 62.

50. (Previously Presented) The method of claim 49, wherein said peptide consists of a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 56, SEQ ID NO: 59, and SEQ ID NO: 62.

51. (Previously Presented) The method of claim 46, wherein said peptide further comprises:

(a) an N-terminal substituent selected from the group consisting of: hydrogen, lower alkyl group that is either acyclic or cyclic and has 1 to 8 carbon atoms, aromatic group, heterocyclic group, and acyl group; and

(b) a C-terminal substituent selected from the group consisting of hydroxy, alkoxy, aryloxy, and unsubstituted and substituted amino groups.

52. (Previously Presented) The method of claim 46, wherein said peptide is conjugated to a carrier.

53. (Previously Presented) The method of claim 52, wherein said carrier is keyhole limpet hemocyanin (KLH).

54. (Canceled).

55. (Currently Amended) The method of claim 46 [[54]], wherein said adjuvant is selected from the group consisting of granulocyte-macrophage colony-stimulating factor, interleukin-12, GM-CSF, synthetic muramyl dipeptide analog, monophosphoryl lipid A, lactic acid bacteria, $Al(OH)_3$, muramyl dipeptides, and saponins.

56. (Previously Presented) The method of claim 46, wherein said anti-amyloidogenic antibodies alter levels of soluble amyloid-β in the brain of said subject.

57. (Previously Presented) The method of claim 46, wherein said anti-amyloidogenic antibodies prevent fibrillogenesis in the brain of said subject.

58. (Previously Presented) The method of claim 46, wherein said amyloid-related disease is a neurodegenerative disorder.

59. (Previously Presented) The method of claim 58, wherein said neurodegenerative disorder is cerebral amyloid angiopathy.

60. (Previously Presented) The method of claim 58, wherein said neurodegenerative disorder is Alzheimer's disease.

61. (Currently Amended) A method for preventing and/or treating Alzheimer's disease in a subject, comprising administering to said subject a vaccine for generating anti-amyloidogenic antibodies, wherein said vaccine comprises a peptide comprising an amino acid sequence as set forth in SEQ ID NO: 13 and an adjuvant, and the amino acids of said SEQ ID NO: 13 consist entirely of [D]-amino acids.

62. (Currently Amended) A vaccine for generating anti-amyloidogenic antibodies in a subject, the vaccine comprising a peptide comprising an amino acid sequence as set forth in SEQ ID NO: 13 and an adjuvant, wherein the amino acids of said SEQ ID NO: 13 consist entirely of [D]-amino acids.

63. (Previously Presented) The vaccine of claim 62, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 56, SEQ ID NO: 59, and SEQ ID NO: 62.

64. (Previously Presented) The vaccine of claim 63, wherein said amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 56, SEQ ID NO: 59, or SEQ ID NO: 62 consists entirely of [D]-amino acids.

65. (Previously Presented) The vaccine of claim 62, wherein said peptide is made entirely of [D]-amino acids and comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 56, SEQ ID NO: 59, and SEQ ID NO: 62.

66. (Previously Presented) The vaccine of claim 65, wherein said peptide consists of a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 50, SEQ ID NO: 53, SEQ ID NO: 56, SEQ ID NO: 59, and SEQ ID NO: 62.

67. (Previously Presented) The vaccine of claim 62, wherein said peptide further comprises:

(a) an N-terminal substituent selected from the group consisting of: hydrogen, lower alkyl group that is either acyclic or cyclic and has 1 to 8 carbon atoms, aromatic group, heterocyclic group, and acyl group; and

(b) a C-terminal substituent selected from the group consisting of hydroxy, alkoxy, aryloxy, and unsubstituted and substituted amino groups.

68. (Previously Presented) The vaccine of claim 62, wherein said peptide is conjugated to a carrier.

69. (Previously Presented) The vaccine of claim 68, wherein said carrier is keyhole limpet hemocyanin (KLH).

70. (Canceled).

71. (Currently Amended) The vaccine of claim 62 [[70]], wherein said adjuvant is selected from the group consisting of granulocyte-macrophage colony-stimulating factor, interleukin-12, GM-CSF, synthetic muramyl dipeptide analog, monophosphoryl lipid A, lactic acid bacteria, $Al(OH)_3$, muramyl dipeptides, and saponins.

72. (Currently Amended) A vaccine for preventing and/or treating Alzheimer's disease in a subject, the vaccine comprising a peptide comprising an amino acid sequence as set forth in SEQ ID NO: 13 and an adjuvant, wherein the amino acids of said SEQ ID NO: 13 consist entirely of [D]-amino acids.